| 2.46 0.11 (4.68%) | 10-31 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 3.89 |
1-year : | 5.11 |
| Resists | First : | 3.33 |
Second : | 4.38 |
| Pivot price | 2.53  |
|||
| Supports | First : | 1.64 |
Second : | 1.37 |
| MAs | MA(5) : | 2.35 |
MA(20) : | 2.62 |
| MA(100) : | 5.98 |
MA(250) : | 0 | |
| MACD | MACD : | -0.8 |
Signal : | -1 |
| %K %D | K(14,3) : | 30.5 |
D(3) : | 21.5 |
| RSI | RSI(14): 37.9 |
|||
| 52-week | High : | 14.3 | Low : | 1.39 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ZYBT ] has closed above bottom band by 40.5%. Bollinger Bands are 80.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 13 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.46 - 2.48 | 2.48 - 2.49 |
| Low: | 2.26 - 2.28 | 2.28 - 2.29 |
| Close: | 2.44 - 2.46 | 2.46 - 2.49 |
Zhengye Biotechnology Holding Limited engages in the research, development, manufacture, and sale of veterinary vaccines for livestock in China. It offers vaccines for swine, cattle, goats, sheep, poultry, and dogs. The company also exports its products to Vietnam, Pakistan, and Egypt. The company was founded in 2004 and is based in Jilin, China. Zhengye Biotechnology Holding Limited operates as a subsidiary of Securingium Holding Limited.
Tue, 28 Oct 2025
Zhengye Biotechnology Holding Limited's (NASDAQ:ZYBT) 26% Share Price Surge Not Quite Adding Up - simplywall.st
Fri, 10 Oct 2025
Zhengye Biotechnology (NASDAQ:ZYBT) Trading Down 11.7% - Time to Sell? - MarketBeat
Sat, 27 Sep 2025
Risks Still Elevated At These Prices As Zhengye Biotechnology Holding Limited (NASDAQ:ZYBT) Shares Dive 79% - 富途牛牛
Sun, 14 Sep 2025
Is Zhengye Biotechnology Holding Limited's (NASDAQ:ZYBT) ROE Of 3.8% Concerning? - Yahoo Finance
Thu, 03 Jul 2025
Zhengye Biotech Earnings: Revenue Falls 12% as Company Pivots to Pet Vaccines with Exclusive Drug Approvals - Stock Titan
Thu, 12 Jun 2025
Zhengye Biotechnology Holding L (ZYBT): Investor Outlook on a Volatile Healthcare Stock with a 52-Week High Potential - DirectorsTalk Interviews
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 47 (M) |
| Shares Float | 4 (M) |
| Held by Insiders | 91.1 (%) |
| Held by Institutions | 0.8 (%) |
| Shares Short | 164 (K) |
| Shares Short P.Month | 190 (K) |
| EPS | 0.02 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.21 |
| Profit Margin | 6 % |
| Operating Margin | 1.6 % |
| Return on Assets (ttm) | 2 % |
| Return on Equity (ttm) | 3.8 % |
| Qtrly Rev. Growth | -3.6 % |
| Gross Profit (p.s.) | 1.92 |
| Sales Per Share | 3.93 |
| EBITDA (p.s.) | 0.85 |
| Qtrly Earnings Growth | -79.6 % |
| Operating Cash Flow | 41 (M) |
| Levered Free Cash Flow | 3 (M) |
| PE Ratio | 82 |
| PEG Ratio | 0 |
| Price to Book value | 0.39 |
| Price to Sales | 0.62 |
| Price to Cash Flow | 2.83 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|